INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update
March 28, 2024 16:01 ET
|
INmune Bio, Inc.
BOCA RATON, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s...
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
March 26, 2024 16:01 ET
|
INmune Bio, Inc.
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, March 26, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a...
INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy
March 13, 2024 08:00 ET
|
INmune Bio, Inc.
International Society for Cell & Gene Therapy (ISCT) Names Dr. Lowdell with the Career Achievement Award in Cell and Gene Therapy Recognizing Exceptional Contributions and...
INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™
March 05, 2024 08:00 ET
|
INmune Bio, Inc.
Patients with Alzheimer’s Disease show improvement in brainwaves following 4 weeks of XPro™ therapy. Boca Raton, Florida, March 05, 2024 (GLOBE NEWSWIRE) --...
INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 12, 2024 09:00 ET
|
INmune Bio, Inc.
Boca Raton, Florida, Feb. 12, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation as a...
INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024
February 06, 2024 09:00 ET
|
INmune Bio, Inc.
Boca Raton, Florida, Feb. 06, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation as...
INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program
January 30, 2024 08:00 ET
|
INmune Bio, Inc.
The Phase II clinical trial in patients with Alzheimer’s disease with neuroinflammation is on track to complete enrollment mid-2024 with top line data expected approximately six months after the...
INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer
January 02, 2024 08:00 ET
|
INmune Bio, Inc.
Boca Raton, Florida, Jan. 02, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the...
INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA
December 18, 2023 16:01 ET
|
INmune Bio, Inc.
Enrollment in the Company’s Phase II study using XProTM to treat patients with Alzheimer’s Disease with neuroinflammation is accelerating in sites outside the US and the Company is maintaining its...
INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium
November 29, 2023 08:00 ET
|
INmune Bio, Inc.
INB03 increases uptake of deruxtecan, the immunotoxin associated with trastuzumab deruxtecan (T-DXd, ENHERTU®), in models of resistant MUC4 expressing HER2 positive breast cancer and increases the...